Jeff Aronin And Paragon Make The Medicines Of The Future
For the past decade, Jeff Aronin has served as CEO of biomedical research company Paragon Biosciences. Their main focus has always been the research and development of new medicines to improve the quality of life for everyone. Over the past decade, they have developed 13 new drugs and gotten them approved by the FDA, and in case you’re wondering, those numbers are almost on par with the larger drug companies.
They have developed medicines to treat the effects of narcolepsy, including excessive daytime sleepiness and cataplexy. They have developed medicines to treat rare genetic dermatological conditions. They have medicines for vitiligo, excessive acne, atopic dermatitis, and premalignant oral lesions. The company has a “process” that they use in order to guide their work. Part of that process is to look for areas of medicine that are neglected and in which patient need is therefore the highest. This explains why they have spent a lot of time researching rare skin afflictions. In some cases, they have developed medicines that are literally the first and only treatment for that particular condition (http://alivenewspaper.com/2018/04/jeff-aronin-saved-desiree-lyon/). That process also includes the identification and support of researchers who have the potential to help the company develop new products. By seeking out and supporting the best researchers, they have developed a good track record for success.
Jeff Aronin has also served as chairman of several other life science companies such as Castle Creek Pharmaceuticals and Harmony Biosciences. He was originally studying to be a physician, but had a life-changing experience when he was assigned to shadow a physician that was treating a child. The child was suffering from constant seizures, and most physicians at the time would have sent him in for major brain surgery. Instead, this physician was able to cure the child through effective application of pharmaceuticals. This motivated Jeff Aronin to get into the pharmaceutical business.
In 2000, he founded Ovation Pharmaceuticals, which he then nursed into a prosperous and effective company as its CEO. In 2009, Jeff Aronin sold the company to Lundbeck for $900 million, but has retained the role of CEO. His business model of seeking out innovation has proven to be both beneficial and profitable.